Click here to listen to the Podcast
- epigenetic biomarkers
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
Epigenetic biomarkers are emerging across tumour types in cancer research. Aberrant DNA methylation in tumours results in silencing of distinct genes. This modification is very stable and therefore can reliably be assessed and used as a diagnostic and prognostic biomarker. Recently, DNA methylation was validated as an additional diagnostic biomarker in brain tumours. Here, the methylation profile allowed precise clinical diagnosis associated with the survival prognosis.1 Therefore, the addition of DNA methylation profiles to routine diagnostic assessment in cancer diagnosis might be promising to ensure accurate diagnosis and support treatment decisions. Further, predictive epigenetic biomarkers were identified, e.g MGMT methylation was repeatably shown to associate with response to alkylating chemotherapy. Several current research efforts are concentrating on the identification of new diagnostic as well as predictive biomarkers in various types of cancer. This podcast provides on overview of the current routinely used biomarkers as well as an outlook on what is on the horizon in epigenetic biomarkers.
Competing interests None declared.
Patient consent Not required.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.